Survival

Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

Wednesday, December 1, 2021 - 11:45pm

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021.
  • Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent cytokine storm in hospitalized patients with COVID-19.

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

Wednesday, December 1, 2021 - 9:15pm

We will continue to evaluate VBI-1901 in the INSIGhT trial, with the hope of providing primary GBM patients alternative treatment options.

Key Points: 
  • We will continue to evaluate VBI-1901 in the INSIGhT trial, with the hope of providing primary GBM patients alternative treatment options.
  • Based on the data seen to date in the Phase 1/2a study in recurrent GBM patients, VBI expects to assess VBI-1901 in randomized, controlled clinical studies in both primary and recurrent GBM patients in the next phase of development.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Christmas Tree Shops to Partner with the Arbor Day Foundation to Plant Trees

Wednesday, December 1, 2021 - 9:58pm

The partnership entails a donation to fund the planting of one tree for each live Christmas tree sold by Christmas Tree Shops.

Key Points: 
  • The partnership entails a donation to fund the planting of one tree for each live Christmas tree sold by Christmas Tree Shops.
  • "We care deeply about our employees, customers and communities," saysPam Salkovitz, CEO of Christmas Tree Shops.
  • "Our partnership with the Arbor Day Foundation will enable us to help beautify the earth and have lasting positiveimpact in areas where Christmas Tree Shops are located."
  • The 50-year-old company has roots in the Northeast with the first store located on Cape Cod, Massachusetts, and today operates 80 stores in 20 states under the banners of Christmas Tree Shops, Christmas Tree Shops andThat!

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

Wednesday, December 1, 2021 - 9:05pm

"We believe orphan-drug designation underscores the recognition of INBRX-109 as a promising therapeutic for patientswith metastatic or unresectable chondrosarcoma, a patient community currently with no other viable options," said Inhibrx Chief Executive Officer Mark Lappe.

Key Points: 
  • "We believe orphan-drug designation underscores the recognition of INBRX-109 as a promising therapeutic for patientswith metastatic or unresectable chondrosarcoma, a patient community currently with no other viable options," said Inhibrx Chief Executive Officer Mark Lappe.
  • Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the United States and the European Union.
  • In January 2021, the FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
  • In June 2021, Inhibrx initiated a randomized, blinded, placebo-controlled, potential registration-enabling Phase 2 trial of INBRX-109 in conventional chondrosarcoma.

MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013

Wednesday, December 1, 2021 - 6:30pm

MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Points: 
  • MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • MaaT013 was investigated in a Phase 2 clinical trial (HERACLES, NCT03359980 ) and is being administered in an early access program in France.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.
  • MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

Cantargia reports opposition against recently granted European patent

Wednesday, December 1, 2021 - 3:09pm

Cantargia has extensive patent protection for IL1RAP-targeting antibodies, through over 100 granted patents globally including therapy and diagnostics of cancer.

Key Points: 
  • Cantargia has extensive patent protection for IL1RAP-targeting antibodies, through over 100 granted patents globally including therapy and diagnostics of cancer.
  • Cantargia today reported that oppositions have been filed by third parties against its recently granted European patent, EP3293202.
  • Our opinion is that the support for the granted patent is solid and that the oppositions are groundless," said Gran Forsberg, CEO of Cantargia.
  • The most recent opposition against one of Cantargia's European patents with claims directed to anti-IL1RAP antibody for treatment of solid tumors expressing IL1RAP, was rejected in its entirety by the European Patent Office.

Love Music. Stop Cancer. campaign launches to benefit lifesaving mission of St. Jude Children's Research Hospital

Wednesday, December 1, 2021 - 2:00pm

to raise awareness and support for kids with cancer and other catastrophic diseases at St. Jude Children's Research Hospital .

Key Points: 
  • to raise awareness and support for kids with cancer and other catastrophic diseases at St. Jude Children's Research Hospital .
  • The campaign is part of a fundraising program called #MusicGives to St. Jude Kids that Jason Thomas Gordon, grandson of St. Jude founder Danny Thomas, founded to continue his grandfather's legacy.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Join the St. Jude mission by visiting stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram and TikTok , and subscribing to its YouTube channel.

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

Wednesday, December 1, 2021 - 2:00pm

These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).

Key Points: 
  • These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).
  • These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS.
  • Details of the presentations are as follows:
    Natural killer (NK) cells are innate lymphocytes that target virus-infected and tumor cells.
  • Their unique phenotypic and gene expression signatures suggest a novel and distinct form of memory-like NK cell governed by tumor-specific signaling pathways.

Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma

Wednesday, December 1, 2021 - 2:01pm

M201: Phase 2 Trial of TGF- Inhibition (OT-101) with Anti-PD-1 (Pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition.

Key Points: 
  • M201: Phase 2 Trial of TGF- Inhibition (OT-101) with Anti-PD-1 (Pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition.
  • OT-101 is a first-in-class anti-TGF- ribonucleic acid (RNA) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials.
  • OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF- RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.
  • OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing.

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab

Wednesday, December 1, 2021 - 2:03pm

Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (4TEEN4) to manufacture and commercialize Procizumab.

Key Points: 
  • Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (4TEEN4) to manufacture and commercialize Procizumab.
  • The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure.
  • We look forward to partnering with 4TEEN4 and working together to develop and manufacture this revolutionary treatment, and help it reach the critical clinical trial phase, said Patricio Massera, Chief Executive Officer at AGC Biologics.
  • 4TEEN4 Pharmaceuticals GmbH (4TEEN4) was established in 2013 in Hennigsdorf near Berlin, Germany, by Dr. Andreas Bergmann, CEO of 4TEEN4, as part of his Medicine4Future Initiative.